Pharmaceutical Technology

FEBRUARY 29, 2024

LUT014 is being investigated in an ongoing Phase II trial as a first-line treatment for EGFR inhibitor-induced acneiform rash, for which there is no approved drug.

FDA 105

FDA 105

Pharmatutor

DECEMBER 27, 2021

AROMATASE INHIBITORS IN BREAST CANCER. Read more about AROMATASE INHIBITORS IN BREAST CANCER Log in or register to post comments Read more about AROMATASE INHIBITORS IN BREAST CANCER Log in or register to post comments About Authors. MANISHA KOTADIYA*, JAYDEEP SAVALIYA. Ahmedabad, Email ID: jaydeepsavaliya27@gmail.com.

Pharma 52

Pharma 52

pharmaphorum

AUGUST 21, 2022

There is still a pressing need for antidepressant therapies that can start to work more quickly than current tricyclic or selective serotonin reuptake inhibitor drugs can take weeks to elevate mood, placing severely affected patients at risk of self harm before they kick in.

FDA 90

FDA Marketing Pharma Sales 90

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. Using this categorization, programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors saw the greatest percentage of RSAs granted. Undoubtedly, this has played a factor in the success of market-leading PD-1 inhibitors, Merck & Co.’s

Marketing 105

Marketing Medicine Leads Safety 105

Pharmaceutical Technology

DECEMBER 15, 2022

Based on the previous 7MM report, growth in the cardiomyopathies market was primarily attributed to the market release of Bristol Myers Squibb’s Camzyos (mavacamten) and the upcoming launch of Cytokinetics’ aficamten, both of which are myosin inhibitors indicated for the management of obstructive hypertrophic cardiomyopathy (HCM).

Marketing 52

Marketing Sales Healthcare Healthcare 52

pharmaphorum

AUGUST 25, 2022

Tecvayli (teclistamab) has been approved by the European Commission for adults with the blood cancer whose disease has progressed have after at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, said J&J.

FDA 94

FDA Marketing Safety Patients 94

pharmaphorum

JULY 25, 2022

The CHMP has backed approval of Tecvayli for adults with relapsed and refractory multiple myeloma who have received at least three prior therapies – including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody – setting up a full approval in the coming weeks.

Medicine 52

Medicine FDA Recruitment Patients 52